Daily Newsletter

19 August 2024

Daily Newsletter

19 August 2024

Amid sales slump, Avantor sells off its clinical services business for $650m

The company has divested its clinical services business to Audax Private Equity to focus on its lab and production businesses.

Phalguni Deswal August 19 2024

Avantor has signed a definitive agreement to divest its clinical services business to a US-based private equity company, Audax Private Equity, for approximately $650m, in a bid to “strengthen its balance sheet”.

The transaction is expected to pull in approximately $475m in cash after taxes, according to Avantor. The divesture is expected to save the company $50m in capitalised leases, with the deal expected to close in Q4 this year.

Avantor plans to use the proceeds from the deal for debt paydown to reduce interest expenses and strengthen the company’s balance sheets. The clinical services business is part of the company's laboratory solutions segment and includes kitting, biorepository, and related equipment and ancillaries.

According to Avantor, the clinical services segment has approximately 800 employees and is expected to generate $200m in revenue this year.

“[The divesture] is an important step for Avantor as we continue to optimise our portfolio in line with our new operating model," said Michael Stubblefield, president and CEO of Avantor.

"The divestiture enables us to enhance our focus on strategic growth opportunities in our lab and production businesses while strengthening our balance sheet. In Audax, we are pleased to have found a new owner that recognises the value proposition of this business and is ideally positioned to invest and grow the platform for the benefit of all stakeholders.”

Avantor has seen the sales of its products decline over the last few months. In 2023, the company reported a 7.3% decrease in net sales, compared to 2022. The downward trend is ongoing, with Avantor reporting a 2.4% decrease in sales in Q2 this year, compared to the same quarter of 2023. The company also reported an adjusted net leverage ratio of 3.9× as of 30 June 2024.

Another medical device entity that sold part of its business to a private equity company this year was UK-based Johnson Matthey, which sold off its medical device components division to European private equity company Montagu in a £550m ($700m) cash transaction.

India's Impact on Medical Devices

India’s medical devices sector has been steadily growing in strength and significance in recent years. The sector benefits from India’s large patient population, rising healthcare expenditure, and growing demand for advanced medical technologies. Additionally, favorable government policies and initiatives aimed at promoting domestic manufacturing and attracting foreign investment have further bolstered the sector’s growth.

India's Impact on Medical Devices

India’s medical devices sector has been steadily growing in strength and significance in recent years. The sector benefits from India’s large patient population, rising healthcare expenditure, and growing demand for advanced medical technologies. Additionally, favorable government policies and initiatives aimed at promoting domestic manufacturing and attracting foreign investment have further bolstered the sector’s growth.

India's Impact on Medical Devices

India’s medical devices sector has been steadily growing in strength and significance in recent years. The sector benefits from India’s large patient population, rising healthcare expenditure, and growing demand for advanced medical technologies. Additionally, favorable government policies and initiatives aimed at promoting domestic manufacturing and attracting foreign investment have further bolstered the sector’s growth.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close